ID   LB5871-LYMP
AC   CVCL_WV42
DR   cancercelllines; CVCL_WV42
DR   DSMZ; ACC-869
DR   DSMZCellDive; ACC-869
DR   Wikidata; Q95981508
RX   PubMed=30277098;
CC   Doubling time: 62 hours (PubMed=30277098); ~70 hours (DSMZ=ACC-869).
CC   Sequence variation: Gene fusion; HGNC; HGNC:990; BCL2 + HGNC; HGNC:5477; IGH; Name(s)=IGH-BCL2 (PubMed=30277098).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (PubMed=30277098).
CC   Sequence variation: Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Pro2139fs (c.6415_6424delCCCCCCTTCA); Zygosity=Heterozygous (PubMed=30277098).
CC   Sequence variation: Mutation; HGNC; HGNC:3373; EP300; Simple; p.Tyr1467Asp (c.4399T>G); Zygosity=Heterozygous (PubMed=30277098).
CC   Sequence variation: Mutation; HGNC; HGNC:11912; TNFRSF14; Simple; p.Trp7Ter (c.20G>A); Zygosity=Heterozygous (PubMed=30277098).
CC   Sequence variation: Mutation; HGNC; HGNC:11912; TNFRSF14; Simple; p.Ala194fs (c.578dup); Zygosity=Heterozygous (PubMed=30277098).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys176Arg (c.526T>C); ClinVar=VCV000376573; Zygosity=Hemizygous (PubMed=30277098).
CC   Derived from site: In situ; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): DSMZ=ACC-869; PubMed=30277098
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,13
ST   D16S539: 9,11
ST   D18S51: 12,16
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 16,17 (DSMZ=ACC-869)
ST   D3S1358: 17 (PubMed=30277098)
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 8,13
ST   FGA: 22,25
ST   Penta D: 9,10 (DSMZ=ACC-869)
ST   Penta D: 10 (PubMed=30277098)
ST   Penta E: 7,11 (PubMed=30277098)
ST   Penta E: 11 (DSMZ=ACC-869)
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 14,15
DI   NCIt; C125904; High grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements
DI   ORDO; Orphanet_480541; High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 19-12-24; Version: 12
//
RX   PubMed=30277098; DOI=10.1080/10428194.2018.1508663;
RA   Dheur M.-S., Poirel H.A., Ameye G., Tilman G., Saussoy P., Defour J.-P.,
RA   Camboni A., Van Den Neste E., Coulie P.G., van Baren N.;
RT   "Characterization of two new high-grade B-cell lymphoma cell lines
RT   with MYC and BCL2 rearrangements that are suitable for in vitro drug
RT   sensitivity studies.";
RL   Leuk. Lymphoma 60:1043-1052(2019).
//